Next Article in Journal
Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL)
Next Article in Special Issue
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
Previous Article in Journal
Bias and Class Imbalance in Oncologic Data—Towards Inclusive and Transferrable AI in Large Scale Oncology Data Sets
Previous Article in Special Issue
The Diagnostic Utility of Cell-Free DNA from Ex Vivo Bronchoalveolar Lavage Fluid in Lung Cancer
 
 
Article

Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC

1
Medical Oncology Department, Hospital Universitario Infanta Leonor, Gran Via del Este 80, 28031 Madrid, Spain
2
Instituto de Investigación Sanitaria del Hospital Universitario la Princesa, 28006 Madrid, Spain
3
Bioinformatics Unit, Spanish National Cancer Research Centre, 28029 Madrid, Spain
4
Medical Oncology Department, Hospital Universitario la Princesa, 28006 Madrid, Spain
5
Department of Medicine and Chair of Personalized Precision Medicine, Universidad Autónoma de Madrid, 28006 Madrid, Spain
6
Medical Oncology Department, Hospital Central de la Defensa Gómez Ulla, 28047 Madrid, Spain
7
Pneumology Department, Hospital Universitario la Princesa, 28006 Madrid, Spain
8
Immunology Department, Hospital Universitario la Princesa, 28006 Madrid, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Giovanni Vicidomini
Cancers 2022, 14(12), 2898; https://doi.org/10.3390/cancers14122898
Received: 9 May 2022 / Revised: 2 June 2022 / Accepted: 6 June 2022 / Published: 12 June 2022
Biomarkers to guide clinical decisions and efficacy are limited in advanced non-small cell lung cancer’s anti-PD-1 immune checkpoint inhibitors. We prospectively explored baseline peripheral blood mononuclear cells in order to asses’ immunotherapy predictors in this setting. We included 39 patients diagnosed with non-small cell lung cancer treated with immunotherapy in the study group and 40 patients with advanced malignancies treated with non-immunotherapy treatment, as control group. We detected that high baseline levels of circulating T cell subpopulations related to tissue lymphocyte recruitment are associated with poorer outcomes of immunotherapy-treated advanced non-small cell lung cancer patients, and these differences were specific to immunotherapy-treated patients.
In lung cancer immunotherapy, biomarkers to guide clinical decisions are limited. We now explore whether the detailed immunophenotyping of circulating peripheral blood mononuclear cells (PBMCs) can predict the efficacy of anti-PD-1 immunotherapy in patients with advanced non-small-cell lung cancer (NSCLC). We determined 107 PBMCs subpopulations in a prospective cohort of NSCLC patients before starting single-agent anti-PD-1 immunotherapy (study group), analyzed by flow cytometry. As a control group, we studied patients with advanced malignancies before initiating non-immunotherapy treatment. The frequency of PBMCs was correlated with treatment outcome. Patients were categorized as having either high or low expression for each biomarker, defined as those above the 55th or below the 45th percentile of the overall marker expression within the cohort. In the study group, three subpopulations were associated with significant differences in outcome: high pretreatment levels of circulating CD4+CCR9+, CD4+CCR10+, or CD8+CXCR4+ T cells correlated with poorer overall survival (15.7 vs. 35.9 months, HR 0.16, p = 0.003; 22.0 vs. NR months, HR 0.10, p = 0.003, and 22.0 vs. NR months, HR 0.29, p = 0.02). These differences were specific to immunotherapy-treated patients. High baseline levels of circulating T cell subpopulations related to tissue lymphocyte recruitment are associated with poorer outcomes of immunotherapy-treated advanced NSCLC patients. View Full-Text
Keywords: non-small cell lung cancer; anti-PD-1 antibodies; immunotherapy; biomarkers; peripheral blood mononuclear cells non-small cell lung cancer; anti-PD-1 antibodies; immunotherapy; biomarkers; peripheral blood mononuclear cells
Show Figures

Figure 1

MDPI and ACS Style

Rogado, J.; Pozo, F.; Troule, K.; Sánchez-Torres, J.M.; Romero-Laorden, N.; Mondejar, R.; Donnay, O.; Ballesteros, A.; Pacheco-Barcia, V.; Aspa, J.; Al-Shahrour, F.; Alfranca, A.; Colomer, R. Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC. Cancers 2022, 14, 2898. https://doi.org/10.3390/cancers14122898

AMA Style

Rogado J, Pozo F, Troule K, Sánchez-Torres JM, Romero-Laorden N, Mondejar R, Donnay O, Ballesteros A, Pacheco-Barcia V, Aspa J, Al-Shahrour F, Alfranca A, Colomer R. Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC. Cancers. 2022; 14(12):2898. https://doi.org/10.3390/cancers14122898

Chicago/Turabian Style

Rogado, Jacobo, Fernando Pozo, Kevin Troule, José Miguel Sánchez-Torres, Nuria Romero-Laorden, Rebeca Mondejar, Olga Donnay, Anabel Ballesteros, Vilma Pacheco-Barcia, Javier Aspa, Fátima Al-Shahrour, Arantzazu Alfranca, and Ramon Colomer. 2022. "Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC" Cancers 14, no. 12: 2898. https://doi.org/10.3390/cancers14122898

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop